BridgeMD
New treatment option for Glioblastoma
Official title A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
ClinicalTrials.gov ID: NCT07093814
What this study is testing
What is VRT106?
VRT106 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for glioblastoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- people voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow...
- Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female.
- Diagnosed with recurrent/progressive glioblastoma.
- Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.
- An expected survival time of≥3 months.
You likely can't join if
- Patients with extracranial metastases.
- Previously received treatment with oncolytic viruses, gene therapy.
- Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106.
- Subject is known to have an allergic reaction to any of the components of VRT106.
- Patients who can't have a cranial MRI scan.
- Women who are breastfeeding.
See the full eligibility criteria
- people voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.
- Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female.
- Diagnosed with recurrent/progressive glioblastoma.
- Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.
- An expected survival time of≥3 months.
- Have sufficient organ function.
- Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first use of the study drug (if a false-positive pregnancy test result is due to non-pregnancy...
- people of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.
- Patients with extracranial metastases.
- Previously received treatment with oncolytic viruses, gene therapy.
- Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106.
- Subject is known to have an allergic reaction to any of the components of VRT106.
- Patients who can't have a cranial MRI scan.
- Women who are breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, Anhui, China
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
- Guangzhou, Guangdong, China
- Shenzhen, Guangdong, China
- Zhuhai, Guangdong, China
- Nanning, Guangxi, China
- Jinan, Shandong, China
- Xi’an, Shanxi, China
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, Anhui, China; Beijing, Beijing Municipality, China; Chongqing, Chongqing Municipality, China; Guangzhou, Guangdong, China; Shenzhen, Guangdong, China; Zhuhai, Guangdong, China and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.